CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: SHIN1, alone or in combination with imatinib, impaired the proliferation of primary CML CD34+ cells, even to a greater extent than imatinib alone (Fig. 6a and Supplementary Fig. 6a).